Crystalline forms of therapeutic compounds and uses thereof

• US 10,626,121 B2
• Filed: 05/17/2019
• Issued: 04/21/2020
• Est. Priority Date: 09/08/2016
• Status: Expired due to Fees

• Current Assignee: Kala Bio, Inc.
• Original Assignee: Kala Pharmaceuticals, Inc.
• Inventors: Nguyen, Minh Ngoc, Ong, Winston Zapanta
• Primary Examiner(s): Ward, Paul V
• Application Number:
  US16/415,848
• Publication Number:
  US 20190270752A1
• Time in Patent Office: 340 Days
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07B 2200/13 Crystalline forms, e.g. polymorphs
• CPC Class Codes: C07D 491/107 with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Abstract

Described herein are crystalline forms of Compound 1 useful for the prevention and treatment of angiogenic ocular conditions; methods of treating a disease comprising; processes for preparing; and kits comprising, the same.

Claims

1. A method of treating a disease comprising administering to a subject in need thereof a therapeutically effective amount of the pharmaceutical composition comprising:

a crystalline form of Compound 1;

2. The method of claim 1, wherein the disease is an ocular disease.

3. The method of claim 1, wherein the disease is retinopathy.

4. The method of claim 1, wherein the disease is age-related macular degeneration (AMD).

5. The method of claim 1, wherein the disease is corneal neovascularization.

6. The method of claim 1, wherein the crystalline form is an anhydrate.

7. A method of inhibiting growth factor signaling comprising administering to a subject a therapeutically effective amount of the pharmaceutical composition comprising:

a crystalline form of Compound 1;

8. The method of claim 7, wherein the crystalline form is an anhydrate.